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lowering therapy be initiated with lifestyle intervention for patients with DM and clinical coronary artery disease (CAD). 9 The concentration of low-density lipoprotein (LDL)-cholesterol in diabetic patients is in general similar to the population average, although they have a large number of atherogenic, small dense LDL particles in the circulation. 10 However, administration of atorvastatin has reduced the risk of cardiovascular disease events in diabetic patients without high LDL-cholesterol levels. 11 On the other hand, treatment with low-dose pravastatin reduced the risk of coronary heart disease (CHD) in Japan by much the same amount as higher doses have shown in Europe and the USA. 12 The Multicenter Study for Aggressive Lipid-lowering Strategy by HMG-CoA Reductase Inhibitors in patients with CHD (MUSASHI) was a PROBE-design trial conducted in normocholesterolemic patients who were randomly assigned to receive either lipidlowering treatment with any available statin or non-statins. The MUSASHI database comprises MUSASHI-AMI (acute MI) 13 and MUSASHI-PCI (percutaneous coronary intervention) patients. In the present study, we reanalyzed the MUSASHI database to examine whether standard-dose statin therapy had a beneficial effect in diabetic CHD patients with normal cholesterol levels.
Methods

MUSASHI Trial and Database
The design of the MUSASHI-AMI trial has been reported already. 13 The MUSASHI-AMI included 486 patients with AMI and 533 patients with stable angina were registered in MUSASHI-PCI. Namely, a total of 1,019 eligible CHD patients who were admitted to 55 medical centers in 19 prefectures of Japan (see Appendix 1) were enrolled between February 2002 and September 2004. Serum total cholesterol levels were required to be 180-240 mg/dl on admission. The AMI patients were randomly assigned within 96 h of symptom onset and stable angina patients were randomly assigned within 48 h of PCI with stratification by center to standard therapy, including open-label treatment with any statin that was available in Japan during the recruitment period (pravastatin, atorvastatin, fluvastatin, simvastatin or pitavastatin) or to standard therapy without statins. The main exclusion criteria for study entry were <18 years of age, use of lipid-lowering agents within the previous 3 months, known familial dyslipidemia, severe renal failure, known hepatic disease, signs and symptoms of severe heart failure (Killip's class III or IV 14 ), scheduled coronary artery bypass grafting (CABG), previous PCI (within 6 months) or CABG (within 3 months), and the presence of malignant disease or allergy to statins. In a total of 1,019 eligible CHD patients enrolled and randomized, 3 patients (1 patient in the statin group and 2 in the non-statin group) were excluded because of insufficient recorded data. The remaining 1,016 patients were included and randomized to the statin group (n=503) or non-statin group (n=513) (Figure 1) . The attending physician was allowed to change the dosage of statins during the study period or to switch from the original statin to another statin, if necessary, but was requested to refrain from using any other lipidlowering medications. All patients received instructions and counseling to enhance compliance with the Japan Atherosclerosis Society Guidelines for Diagnosis and Treatment of Atherosclerotic Cardiovascular Diseases Step I diet. 15 Laboratory testing was performed locally at 6 months, 1 year and 2 years after enrollment to examine lipid profiles and to check for the side-effects of statins. The MUSAHI trial was performed in accordance with the ethical principles of the 
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Declaration of Helsinki and was approved by the local ethics committees or institutional review boards. Written informed consent was given by all patients.
Study Patients
Among the 1,016 patients randomly assigned to standard therapy with or without statins, a total of 301 were recognized as having type 2 DM. The DM group consisted of 301 patients (155 with statin therapy, 146 without statin therapy) and the non-DM group consisted of 715 patients (348 with statin therapy, 367 without statin therapy) (Figure 1) . Type 2 DM was defined as a physician-diagnosed history, treatment with an oral hypoglycemic agent, fasting blood glucose level ≥126 mg/dl at baseline or a 2-h postload glucose level >200 mg/dl during an oral glucose tolerance test. 16 
Endpoints
The endpoint was defined as a cardiovascular death, nonfatal AMI, unstable angina, heart failure, and/or nonfatal stroke. A diagnosis of unstable angina was based on recurrent symptomatic myocardial ischemia with objective evidence that it required emergency rehospitalization. Heart failure was defined as dyspnea and/or edema that required hospitalization and was accompanied by pulmonary congestion on the chest roentgenogram and left ventricular dysfunction on echocardiography. Stroke was diagnosed by the presence of a neurologic deficit that was confirmed by computed tomography or magnetic resonance imaging. The composite of cardiovascular death, nonfatal AMI, unstable angina, heart failure and stroke was defined as major adverse cardiovascular and cerebrovascular events (MACCE).
Statistical Analysis
All statistical analyses were conducted with SAS 8.2 (SAS Institute, Cary, NC, USA). Differences in the characteristics of the patients in the 2 treatment groups were evaluated with Student's t-test for continuous variables and with the chisquare test for absolute categorical variables. The endpoint was the time from admission to a specified event. We plotted the cumulative event curves by Kaplan-Meier survival methods and tested differences between curves for statistical significance by log-rank test. The relative risk reduction (RRR) was calculated by dividing the absolute risk reduction (the difference between the event rate without statin therapy and that with statin therapy) by the control event rate (event rate without statin therapy). The number needed to treat (NNT) was defined as the inverse of the absolute risk reduction. The interaction between DM and statin therapy was statistically tested using a Cox's proportional hazards model in the whole cohort of 1,016 patients. The difference in LDLcholesterol levels between patients treated with and without statins was examined by repeated measures ANOVA using PROC MIXED statement to assess the effect of statin treatment with or without DM over time. Differences with P<0.05 were considered statistically significant. Data are presented as mean ± SD.
Results
Table shows the background of the patients. Apart from age, the demographic and clinical characteristics were comparable between statin and non-statin therapy in the DM and non-DM groups. Figure 2 shows the types of statins used and . The percent reduction in LDL-cholesterol level from baseline in the DM and non-DM groups was 27% and 25% at 6 months, 25% and 27% at 1 year, 29% and 28% at 2 years, respectively. In contrast, the 
Statin Therapy in DM Patients
LDL-cholesterol levels without statin treatment decreased by 4% and 4% at 6 months, 5% and 6% at 1 year, 3% and 8% at 2 years in the DM and non-DM groups, respectively. The statin effect was significant when averaged over all measurement times (P<0.0001). Additionally, the time effect and time-by-statin treatment interaction were also significant (P< 0.0001), which indicates that the impact of statin therapy became large as time passed (Figure 3) . In the DM group, the levels of high-density lipoprotein (HDL)-cholesterol and triglyceride were comparable between statin and non-statin Hazard ratio for major adverse cardiovascular and cerebrovascular events (composite of cardiovascular death, nonfatal acute myocardial infarction, unstable angina, heart failure and stroke). CI, confidence interval; DM, diabetes mellitus; MI, myocardial infarction.
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therapy during the follow-up period. However, statins significantly increased HDL-cholesterol levels at 6 months (50± 13 vs 47±13 mg/dl, P=0.002), 1 year (51±14 vs 48±13 mg/dl, P=0.007) and 2 years (51±13 vs 48±14 mg/dl, P=0.01), and decreased triglyceride levels at 6 months (138±88 vs 152± 74 mg/dl, P=0.02) and 1 year (133±66 vs 153±78 mg/dl, P= 0.002) compared with non-statin therapy in the non-DM group. A total of 123 patients (54 from MUSASHI-AMI, 69 from MUSASHI-PCI) underwent MACCE during a mean followup period of 547±262 days. The MACCE occurred in 9 patients (6%) treated with statins (unstable angina: 6, stroke: 3) and 26 (18%) without statins (cardiovascular death: 1, unstable angina: 19, heart failure: 4, stroke: 2) in the DM group and in 37 patients (11%) treated with statins (cardiovascular death: 3, non-fatal AMI: 7, unstable angina: 17, heart failure: 6, stroke: 4) and 51 (14%) without statins (cardiovascular death: 1, non-fatal AMI: 3, unstable angina: 35, heart failure: 9, stroke: 3) in the non-DM group. The number of MACCE did not differ according to the type of statin used (18 patients [7%] with hydrophilic statins, 28 patients with lipophilic statins [11%], P=0.228 [log-rank]). Statin treatment decreased the MACCE in both the DM and non-DM groups; however, the NNT and RRR were remarkable in the DM group especially (NNT=8, RRR=67%, P=0.002) compared with the non-DM group (NNT=30, RRR=24%, P=0.257) (Figure 4 ). An interaction between DM and statin therapy was observed (P-value for interaction=0.041). There were no significant differences in the risk of cardiovascular deaths, nonfatal AMI, heart failure, and stroke between statin and non-statin treatments in the DM and non-DM groups. In contrast, in both groups statin treatment showed a lower onset of unstable angina that required emergency rehospitalization ( Figure 5) .
Discussion
In the present study, we demonstrated that standard-dose statin therapy reduced LDL-cholesterol levels approximately 100 mg/dl in the DM and non-DM groups with CHD during the follow-up period. The RRR was marked in DM patients treated with statins compared with those not treated with statins. Statin treatment was especially associated with a lower incidence of unstable angina in both the DM and non-DM patients.
Intensive blood glucose control reduces the risk of microvascular complications, but not macrovascular diseases in diabetic patients. 7,17,18 If anything, severe hypoglycemia is more common in patients with intensive blood glucose lowering therapy. 17, 18 On the other hand, the antidiabetic agent, pioglitazone, reduces the composite of all-cause mortality, non-fatal MI, and stroke in diabetic patients with macrovascular diseases. 8 However, the RRR is unexpectedly low and there may be a limitation to the reduction of cardiovascular events by antidiabetic agents. High concentrations of LDL-cholesterol and low concentrations of HDL-cholesterol are strong risk factors for CHD, 19 and pravastatin and atorvastatin were efficacious in reducing the risk of cardiovascular disease events in diabetic patients. 11,20 These findings strengthen the evidence for more widespread use of statins for primary prevention of CHD in diabetic patients. However, there is no evidence that statins can secondarily prevent CHD in diabetic patients.
DM is a strong predictor of coronary plaque volume in CHD patients. 21 Moreover, intravascular ultrasonography demonstrated that coronary plaque in diabetic patients is lipidrich with a thin fibrous cap. 22 Kawasaki et al reported that pravastatin or atorvastatin therapy for 6 months decreased the plaque lipid component and increased the fibrous component without reducing plaque volume following a reduction of serum LDL-cholesterol from 150 to nearly 100 mg/dl. 23 The direct actions of lipid-lowering therapy with statins include modification of the process of atherosclerosis progression and stabilization of atheromatous plaque, implying changes in plaque content, such as removal of lipids from lipid-rich plaques and increased fibrous tissue content.
The National Cholesterol Education Program Adult Treatment Panel recommended an optimal LDL goal of <70 mg/dl for patients with the highest risk, including those with cardiovascular diseases with additional high-risk factors such as DM, multiple cardiovascular risk factors and severe or poorly controlled risk factors, especially smoking. 24 However, we demonstrated that statin treatment effectively and substantially reduced MACCE in diabetic patients in spite of using standard-dose statins, which produced mild lowering of LDLcholesterol levels to approximately 100 mg/dl. Pravastatin and atorvastatin were frequently prescribed in the present study, although the exact mechanisms underlying the improvement of prognosis of diabetic CHD patients have not been elucidated. Multifactorial risks such as hyperglycemia, diabetic dyslipidemia, and inflammation may link accelerated vascular injury and progression of cardiovascular diseases. 10 Recent studies have shown that statins might have cholesterol-independent effects that include improving endothelial function, reducing vascular inflammation, inhibiting smooth muscle cell proliferation, an antithrombotic effect and immunomodulation. [25] [26] [27] In this regard, we demonstrated previously that statins reduce the onset of symptomatic congestive heart failure in addition to recurrent symptomatic myocardial ischemia in patients with AMI. 13 Taken together, it seems that statins could improve the prognosis of diabetic CHD patients through direct and pleiotropic effects.
Study Limitations
The present study is based on a subanalysis of the MUSASHI database and is limited to the Japanese population. Patients having serum total cholesterol levels of 180-240 mg/dl were recruited in the MUSASHI trial. However, the period prevalence of DM, the type of antidiabetic agents used, and control of blood glucose or hemoglobin A1c in the DM and non-DM patients for the follow-up period were not investigated and these factors may have had some effects on the results of this study. Moreover, the risk reduction when treated with statins was greater in the DM groups compared with the non-DM groups. Namely, there was an interaction between statin treatment and DM for MACCE. The cause is unknown but there may be several biases in the data setting of this study. Further studies of larger populations, including other ethnic groups, are needed to confirm our findings.
We conclude that standard-dose statin therapy provides incremental clinical benefits in DM patients with normal cholesterol levels compared with non-DM patients. Our data suggest that DM patients may benefit from the pleiotropic effects of statins, independent of the LDL-cholesterol-lowering effects of these agents.
